- Home
- IP vs NTRA Comparison
IP vs NTRA Comparison
Compare IP & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IP
- NTRA
- Stock Information
- Founded
- IP 1898
- NTRA 2003
- Country
- IP United States
- NTRA United States
- Employees
- IP N/A
- NTRA N/A
- Industry
- IP Paper
- NTRA Medical Specialities
- Sector
- IP Basic Materials
- NTRA Health Care
- Exchange
- IP Nasdaq
- NTRA Nasdaq
- Market Cap
- IP 26.2B
- NTRA 21.7B
- IPO Year
- IP N/A
- NTRA 2015
- Fundamental
- Price
- IP $48.67
- NTRA $168.02
- Analyst Decision
- IP Buy
- NTRA Strong Buy
- Analyst Count
- IP 7
- NTRA 16
- Target Price
- IP $56.71
- NTRA $193.50
- AVG Volume (30 Days)
- IP 3.6M
- NTRA 1.2M
- Earning Date
- IP 10-30-2025
- NTRA 08-07-2025
- Dividend Yield
- IP 3.80%
- NTRA N/A
- EPS Growth
- IP N/A
- NTRA N/A
- EPS
- IP N/A
- NTRA N/A
- Revenue
- IP $21,934,000,000.00
- NTRA $1,964,250,000.00
- Revenue This Year
- IP $45.90
- NTRA $23.93
- Revenue Next Year
- IP $5.45
- NTRA $15.60
- P/E Ratio
- IP N/A
- NTRA N/A
- Revenue Growth
- IP 18.13
- NTRA 44.38
- 52 Week Low
- IP $43.27
- NTRA $110.57
- 52 Week High
- IP $60.36
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- IP 49.79
- NTRA 62.59
- Support Level
- IP $47.32
- NTRA $156.71
- Resistance Level
- IP $49.57
- NTRA $170.72
- Average True Range (ATR)
- IP 0.99
- NTRA 4.62
- MACD
- IP 0.13
- NTRA 0.39
- Stochastic Oscillator
- IP 67.78
- NTRA 80.73
About IP International Paper Company
International Paper manufactures packaging products and cellulose fibers. It accounts for roughly one-third of the North American corrugated packaging market. The company also has a substantial presence in Europe following its acquisition of DS Smith. International Paper serves a variety of end markets, including industrial, consumer products, and manufacturing.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.